Summary: South Korean-based Stand Up Therapeutics Co., Ltd. is a gene therapy

firm for paralysed individuals with spinal cord damage. Stand Up Therapeutics

said that it had inked a contract with VectorBuilder Inc., a global leader in

gene delivery technologies, to produce a GMP-grade gene delivery system.

Seoul, South Korea--(Newsfile Corp. - January 11, 2023) - Stand Up

Therapeutics Co., Ltd. has emerged as a gene therapy firm where Stand Up

Therapeutics and VectorBuilder announced the initiative to supply the initial

paraplegic patient's gene therapy materials. According to Stand Up

Therapeutics, VectorBuilder will create and distribute gene therapy products

designed by Stand Up Therapeutics in the future under this arrangement. The

objective is to control the global market.

Chief Scientist of VectorBuilder Bruce Lahn stated, "VectorBuilder is

particularly interested in Stand Up Therapeutics' gene therapy for the global

treatment of paralysis. As a global pioneer in the design and GMP manufacture

of gene delivery vectors, I am hopeful that VectorBuilder will have the

opportunity to sell this product to Stand Up for patients worldwide."

VectorBuilder is the world's largest provider of customized vectors for viral

and non-viral gene delivery, operating as a multinational corporation with

offices in North America, Europe, China, Japan, Korea, Australia, and Israel.

The company is headquartered in Chicago, Illinois, and has offices in North

America, Europe, China, Japan, Korea, Australia, and Israel. Currently, more

than 80,000 bespoke vectors are created each year for scholars all around the

world. VectorBuilder has GMP facilities for gene delivery systems and provides

gene therapy products and delivery systems to tens of thousands of

institutions and over 50,000 customers, including the world's top

pharmaceutical corporations and universities. VectorBuilder provides gene

therapy items and delivery mechanisms.

Dr. Junsang Yoo, the chief executive officer of Stand Up Therapeutics, stated,

"Stand Up Therapeutics is the only company in the world with the technology to

treat paralysed patients as a result of spinal cord damage utilising its own

developed direct lineage reprogramming technique (STUP-001)." The members of

Stand Up Therapeutics are devoting their whole efforts to the development of a

treatment for people with paralysis caused by catastrophic damage. Also,

"Stand Up Therapeutics hopes to develop treatments for Parkinson's disease

(STUP-002), stroke (STUP-003), spinal stenosis (STUP-004), and myocardial

infarction (STUP-005) in the future using the direct cross-differentiation

PIPELINE technology."

STUP-001, a gene therapy treatment for spinal cord injury (SCI), will enter

the IIT Clinical phase I/IIa research in the first quarter of 2023 with four

paraplegic patients.

                            Stand Up Therapeutics

About Stand Up Therapeutics Co., Ltd.

Using cutting-edge technologies, Stand Up Therapeutics Co., Ltd. develops gene

therapies for nerve cell regeneration by transforming fibroblasts into motor

neurons in vivo. Stand Up Therapeutics intends to deploy direct lineage

reprogramming technology to treat mild and severely paralysed patients, who

make up approximately 1.9% of the world's population and have suffered spinal

cord and brain injuries. Stand Up Therapeutics will expand its pipeline

through the development of safer and more effective direct reprogramming

techniques and gene therapy.